Explore

Discover dailyDiscover daily
What Happens When Your Body Needs New Skin?

What Happens When Your Body Needs New Skin?

Plastic surgery, at its core, is about the art of reshaping and restoring, a concept rooted in the Greek term "plastike (tekhne)," meaning "the art...
Rapid ReadRapid Read
Anticoagulation Reversal Decisions Evolve for Orthopedic Trauma Surgery Patients

Anticoagulation Reversal Decisions Evolve for Orthopedic Trauma Surgery Patients

The approach to anticoagulation reversal before urgent orthopedic trauma and fracture surgery is undergoing a significant shift. Historically, there was a "dogmatic approach" of waiting for anticoagulation reversal or for bleeding risk to reach an acceptable level before surgery. However, medical teams and orthopedic specialists now recognize the critical importance of early mobilization for these patients, particularly those with hip fractures. The morbidity associated with delaying surgery for 24 to 48 hours, especially for elderly patients with fragility fractures, is often greater than the risk of blood loss during an earlier intervention. This realization has led to a growing body of literature supporting early intervention. While direct oral anticoagulants (DOACs) are becoming more common, a subset of patients still use warfarin, which requires careful management. The decision-making process now emphasizes communication between orthopedic, anesthesia, and medicine teams to assess patient profiles, co...
Rapid ReadRapid Read
Patricia's Battle with Small Cell Lung Cancer Highlights Promise of T-Cell Engager Clinical Trial at Roswell Park

Patricia's Battle with Small Cell Lung Cancer Highlights Promise of T-Cell Engager Clinical Trial at Roswell Park

Patricia, a patient at Roswell Park Comprehensive Cancer Center, is experiencing an exceptional response to a Phase 1 clinical trial for small cell lung cancer (SCLC) using a new T-cell engager drug. Diagnosed with aggressive Stage 4 SCLC after already undergoing treatment for a brain tumor, Patricia initially felt unheard about her declining health. After transferring to Roswell Park and meeting with medical oncologist Dr. Prantesh Jain, she learned about the clinical trial. T-cell engagers are a type of immunotherapy that works by directing a patient's own immune system T cells to target and destroy cancer cells. This specific study drug targets a protein called delta-like ligand 3 (DLL3), found on most SCLC cells. A year into the trial, Patricia's lung tumors are shrinking, with one 40% smaller, and there is currently no evidence of disease progression. She attributes her improved health and renewed hope to the trial and the supportive care received at Roswell Park.
Rapid ReadRapid Read
HeartBeam Receives FDA Breakthrough Device Designation for At-Home Heart Attack Assessment

HeartBeam Receives FDA Breakthrough Device Designation for At-Home Heart Attack Assessment

HeartBeam, Inc., a medical technology company, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its HeartBeam System. This designation recognizes the system's potential as a tool for assessing suspected heart attacks (myocardial infarction, or MI) in a non-hospital setting, specifically at home. The technology utilizes 3D ECG to capture the heart's electrical signals from three non-coplanar dimensions, enabling physicians to evaluate potential heart attacks when symptoms first appear, regardless of the patient's location. The FDA's decision came within 30 days of HeartBeam's request, significantly faster than the typical 60-day review period. This system builds upon HeartBeam's existing FDA-cleared arrhythmia assessment product, leveraging the same 3D ECG platform without requiring new hardware development. The company estimates the MI market opportunity at approximately $15 billion.
SB NationSB Nation
Jim Ross scheduled for a second brain surgery this week

Jim Ross scheduled for a second brain surgery this week

JR had a shunt inserted in his brain about two months ago.
Rapid ReadRapid Read
HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

The U.S. Department of Health and Human Services (HHS) has announced a new program and three complementary projects aimed at significantly speeding up clinical trials through the integration of artificial intelligence (AI), advanced computational models, and real-time analysis. The core initiative, named SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), seeks to develop AI-powered platforms that will continuously and adaptively support clinical trial designs. This program includes the creation of a phaseless design engine to simulate trials for faster results with fewer patients, a continuous inference engine for real-time data analysis and trial adaptations, and an agentic AI operations layer to automate startup activities and data collection. These efforts are part of a broader strategy by HHS to transform U.S. clinical trials, building on previous initiatives like Operation TrialBlazer and the FDA's pilot program using AI for real-time clinical trial data monitoring. The goal ...
Rapid ReadRapid Read
Mayo Clinic Recognized as Top-Ranked Healthcare Provider, Offers Comprehensive Employee Benefits

Mayo Clinic Recognized as Top-Ranked Healthcare Provider, Offers Comprehensive Employee Benefits

Mayo Clinic has been recognized by U.S. News & World Report as the top-ranked care provider in more specialties than any other institution. This not-for-profit organization operates three main campuses in Phoenix/Scottsdale, Arizona; Jacksonville, Florida; and Rochester, Minnesota, along with additional locations across Midwestern communities and internationally. The institution emphasizes a patient-first approach while also prioritizing its employees through competitive compensation and extensive benefit packages. These benefits include multiple medical plan options, Delta Dental or a reimbursement account for dental coverage, an affordable vision plan with a national network, pre-tax savings options like HSAs and FSAs, and a competitive retirement package. Mayo Clinic also promotes continuous education and career advancement opportunities, aiming to foster long-term employee success.
Rapid ReadRapid Read
Scientists Uncover Systemic Body Changes After Three Days of Fasting

Scientists Uncover Systemic Body Changes After Three Days of Fasting

A study involving 12 healthy volunteers, conducted by scientists from the Precision Healthcare University Research Institute at Queen Mary University of London and the Norwegian School of Sport Sciences, has revealed significant systemic changes in the human body after approximately three days of complete calorie restriction. Participants underwent a seven-day water-only fast, with researchers monitoring blood markers daily. The study, published in Nature Metabolism in 2024, found that after about three days, pronounced changes occurred in the levels of proteins associated with various organs, with roughly one in three measured proteins showing significant alteration. These effects were linked to all major organs and could not be solely attributed to weight loss. During the initial two to three days, the body transitioned from using glucose to fat stores for energy. Participants lost an average of 5.7 kilograms, comprising both fat and lean mass. After refeeding, most lost lean mass recovered, while the re...
TrendlineTrendline
ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer Amidst Ongoing Alzheimer's Drug Trial

ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer Amidst Ongoing Alzheimer's Drug Trial

ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer Amidst Ongoing Alzheimer's Drug Trial
Rapid ReadRapid Read
Guardant Health's Liquid Biopsy Test Validated for Melanoma Recurrence Prediction

Guardant Health's Liquid Biopsy Test Validated for Melanoma Recurrence Prediction

Guardant Health, Inc. announced that results from its COSMOS-MEL01 study have been published in Cancer Research Communications. This study validates the utility of the Guardant Reveal™ liquid biopsy test for detecting molecular residual disease (MRD) and predicting recurrence in patients with resected stage II–III melanoma. The study, which is the first prospective, multicenter evaluation of this tissue-free, epigenomic blood test in resected melanoma, analyzed 280 longitudinal surveillance samples from 48 patients. Key findings indicate that circulating tumor DNA (ctDNA) detection after surgery was strongly associated with recurrence and melanoma-related death. The Guardant Reveal test demonstrated 81% sensitivity for distant recurrences and 100% specificity in post-treatment samples from recurrence-free patients. Notably, ctDNA detection often preceded clinical identification of recurrence by a median of 70.5 days. This suggests the test can provide earlier identification of high-risk patients.
Rapid ReadRapid Read
CRISPR Gene Therapies Advance Towards Direct In-Body Genome Editing for Inherited Retinal Disease

CRISPR Gene Therapies Advance Towards Direct In-Body Genome Editing for Inherited Retinal Disease

CRISPR gene editing therapies are progressing from ex vivo (outside the body) modifications to direct in-vivo (inside the body) genome editing. A significant development in this area is the BRILLIANCE clinical trial, which in 2020 treated its first patient with EDIT-101, an experimental CRISPR/Cas9 therapy for Leber congenital amaurosis type 10 (LCA10). LCA10 is a rare inherited retinal disorder caused by mutations in the CEP290 gene. The treatment involves a subretinal injection designed to deliver the editing machinery directly to retinal cells. The eye is considered an ideal environment for such research due to its contained tissue, allowing for localized treatment delivery. While this represents a major step forward, researchers emphasize that these results should not be mistaken for an established human clinical therapy. The field is also exploring in-vivo approaches for other tissues, such as the liver, using lipid nanoparticles for systemic administration, with some experimental programs already in ...
Rapid ReadRapid Read
Florida Expands Newborn Genetic Testing for Rare Diseases, Aiding Early Diagnosis

Florida Expands Newborn Genetic Testing for Rare Diseases, Aiding Early Diagnosis

The state of Florida has enacted a law establishing a program to offer genetic testing to all newborn families, aiming for early detection of rare diseases. This initiative comes as a Gainesville boy, Denny Ladkani, living with Duchenne Muscular Dystrophy, prepares for gene therapy. His family experienced difficulties in obtaining a diagnosis for several years, highlighting the challenges associated with rare genetic conditions. The new state program seeks to address such diagnostic delays by providing opportunities for families to identify potential rare diseases at the earliest possible stage. Denny's upcoming gene therapy treatment requires a six-week quarantine, leading his friends and family to organize a drive-by birthday parade to show support. This personal story underscores the critical need for early diagnosis and access to advanced treatments for rare genetic disorders.